Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral sedative for children

A sedative and children's technology, applied in the direction of medical preparations of non-active ingredients, drug delivery, active ingredients of hydroxyl compounds, etc., can solve problems such as unpredictable vomiting, vomiting, and physical injury of children

Active Publication Date: 2015-07-29
赵柏松
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] But chloral hydrate mouthfeel is very poor, has very strong bitter taste and pungent taste, and infants and young children can appear violent crying resistance when oral; It is easy to vomit after being stimulated, which leads to vomiting of the medicine that has been taken, and because the amount of medicine vomited out cannot be estimated, if it is taken orally again, it may lead to excessive drug intake and poisoning, which will cause various inspections of the disease to be unable to be carried out; and if The method of enema administration to sick children must be fixed by compulsory measures before the liquid can be poured in. In the process of forcing the children to act, it is easy to cause physical harm to the children and affect the treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral sedative for children
  • Oral sedative for children

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 2

[0014] Implementation method 2: select mass concentration as 15% chloral hydrate solution 20ml, simple syrup 15ml, mass concentration 10% glucose 10ml, sodium citrate 800mg, after sodium citrate 800mg is dissolved in 10% glucose solution earlier, 20ml Chloral hydrate solution, simple syrup 15ml, and glucose dissolved in sodium citrate were mixed, and the mixed solution was placed in a drug shaker and shaken at room temperature for 4 hours to form a solution with a pH value of 7.5, and the oral sedative was completed. configuration.

Embodiment approach 3

[0015] Implementation method 3: select mass concentration as 20% chloral hydrate solution 20ml, simple syrup 20ml, mass concentration 5% glucose 10ml, sodium citrate 800mg, after sodium citrate 800mg is dissolved in 5% glucose solution earlier, 20ml Chloral hydrate solution, simple syrup 20ml, and glucose dissolved in sodium citrate were mixed, and the mixed solution was placed in a drug shaker and shaken at room temperature for 4 hours to form a solution with a pH value of 7.8, and the oral sedative was completed. configuration.

[0016] The oral sedatives for children configured above were tested after all participating children were reviewed and approved by the hospital ethics committee, and their families signed the informed consent. A total of 120 children who needed to be sedated for examination were selected, ASA Ⅰ-Ⅱ grade, aged 1 month to 3 years old, and those with a history of allergy to chloral hydrate and severe liver and kidney dysfunction were excluded from the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an oral sedative for children. The oral sedative comprises the following components: simple syrup, a chloral hydrate solution with the mass concentration of 10%-20%, and a glucose solution, containing sodium citrate, with the mass concentration of 5%-10% according to the volume proportion of the (1-2):2:1, wherein the mass concentration of the glucose solution dissolving sodium citrate is 5%-10%; the main simple syrup component is the simple syrup of cane sugar, and the mixed oral sedative is a weak alkaline solution with the pH value of 7-8. According to the sedative formula of the application, (1) the taste of the conventional chloral hydrate is improved, and the conflict reaction when the sedative is taken by an infant patient is reduced; (2) the effect-taking time of the oral chloral hydrate sedative is shortened, so that the sedative can be absorbed by small intestines relatively easily, the bioavailability is improved, the stimulation on gastrointestinal tracts is reduced, and nausea and vomiting are reduced.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and more precisely relates to a sedative pharmaceutical preparation, in particular to an oral sedative for infants and young children. Background technique [0002] Sedative drugs are mainly used in the treatment of mental diseases. Their main effect is to relieve people's depression and anxiety, and to treat inability to sleep caused by mental stress. Commonly used sedative drugs include phenobarbital, meproton, chlordiazepoxide, and diazepam. However, the use of these drugs is strictly restricted to pregnant women and children. Even people with normal health who take stable sedative drugs for a long time will have side effects: drowsiness, inability to concentrate, unresponsiveness, memory loss, dizziness, etc. [0003] For children with mental stress, especially children who are examined in general pediatrics, blood tests and other tests are usually required to diagnose th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K31/047A61K47/26A61K47/12A61P25/20
Inventor 赵柏松
Owner 赵柏松
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products